National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
Topics
- Arthritis (1)
- Children/Adolescents (2)
- COVID-19 (1)
- Elderly (1)
- Evidence-Based Practice (1)
- Healthcare Costs (2)
- Health Promotion (1)
- Human Immunodeficiency Virus (HIV) (1)
- Infectious Diseases (3)
- Influenza (3)
- Long-Term Care (1)
- Nursing Homes (1)
- Pneumonia (1)
- (-) Prevention (10)
- Provider: Health Personnel (1)
- Public Health (2)
- Racial and Ethnic Minorities (1)
- Respiratory Conditions (1)
- Sexual Health (2)
- Urban Health (1)
- (-) Vaccination (10)
- Women (2)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 10 of 10 Research Studies DisplayedBartsch SM, O'Shea KJ, Ferguson MC
Vaccine efficacy needed for a COVID-19 coronavirus vaccine to prevent or stop an epidemic as the sole intervention.
This study examined the needed efficacy and coverage of a COVID-19 vaccine to prevent or stop the pandemic. Simulation experiments were conducted at 60-80% efficacy rates. At 60% efficacy, vaccination coverage needs to be 100%. If the coverage rate is reduced to 75%, the efficacy needs to be 70% and up to 80% when coverage drops to 60%. These findings show that the vaccine needs to have at least an efficacy rate of 70% to prevent an epidemic and at least 80% to extinguish an epidemic without any other measures such as social distancing.
AHRQ-funded; HS023317.
Citation: Bartsch SM, O'Shea KJ, Ferguson MC .
Vaccine efficacy needed for a COVID-19 coronavirus vaccine to prevent or stop an epidemic as the sole intervention.
Am J Prev Med 2020 Oct;59(4):493-503. doi: 10.1016/j.amepre.2020.06.011..
Keywords: Vaccination, COVID-19, Public Health, Prevention, Evidence-Based Practice, Infectious Diseases
Bartsch SM, Asti L, Stokes-Cawley OJ
The potential economic value of a Zika vaccine for a woman of childbearing age.
The authors mapped the Zika vaccine and vaccination characteristic thresholds at which vaccination becomes cost effective, highly cost effective, and cost saving. They developed a Markov model to simulate a woman of childbearing age to follow the potential risk and clinical course of a Zika infection. They found that, in some cases, the vaccine was cost effective when the risk was as low as 0.015%, the cost was as high as $7,500, the efficacy was as low as 25%, and the duration of protection was 1 year. They concluded that the thresholds at which vaccination becomes cost effective and cost saving can provide targets for Zika vaccine development and implementation.
AHRQ-funded; HS023317.
Citation: Bartsch SM, Asti L, Stokes-Cawley OJ .
The potential economic value of a Zika vaccine for a woman of childbearing age.
Am J Prev Med 2020 Mar;58(3):370-77. doi: 10.1016/j.amepre.2019.10.023..
Keywords: Vaccination, Women, Infectious Diseases, Public Health, Healthcare Costs, Prevention
Albright K, Hurley LP, Lockhart S
Attitudes about adult vaccines and reminder/recall in a safety net population.
The objective of this study was to determine patient perspectives on adult vaccines generally; attitudes about Tdap, pneumococcal polysaccharide (PPSV-23), and seasonal influenza vaccines specifically; and preferences for adult reminder/recall delivery.
AHRQ-funded; HS022648.
Citation: Albright K, Hurley LP, Lockhart S .
Attitudes about adult vaccines and reminder/recall in a safety net population.
Vaccine 2017 Dec 19;35(52):7292-96. doi: 10.1016/j.vaccine.2017.11.001..
Keywords: Influenza, Pneumonia, Vaccination, Prevention, Respiratory Conditions
Adamson BJS, Carlson JJ, Kublin JG
The potential cost-effectiveness of pre-exposure prophylaxis combined with HIV vaccines in the United States.
This economic evaluation found that at current prices, pre-exposure prophylaxis (PrEP) was not cost-effective alone or in combination. A combination strategy had the greatest health benefit but was not cost-effective as compared to vaccination alone. Vaccine durability and PrEP drug prices were key drivers of cost-effectiveness.
AHRQ-funded; HS013853.
Citation: Adamson BJS, Carlson JJ, Kublin JG .
The potential cost-effectiveness of pre-exposure prophylaxis combined with HIV vaccines in the United States.
Vaccines 2017 May 24;5(2). doi: 10.3390/vaccines5020013.
.
.
Keywords: Human Immunodeficiency Virus (HIV), Vaccination, Healthcare Costs, Prevention
Baldwin AS, Denman DC, Sala M
Translating self-persuasion into an adolescent HPV vaccine promotion intervention for parents attending safety-net clinics.
Researchers developed a tablet-based application (in English and Spanish) to elicit parental self-persuasion for adolescent HPV vaccination and evaluated its feasibility in a safety-net population. They found that the self-persuasion application was feasible and resulted in a change in parents' decision stage. Future studies can now test the efficacy of the tablet-based application on HPV vaccination.
AHRQ-funded; HS022418.
Citation: Baldwin AS, Denman DC, Sala M .
Translating self-persuasion into an adolescent HPV vaccine promotion intervention for parents attending safety-net clinics.
Patient Educ Couns 2017 Apr;100(4):736-41. doi: 10.1016/j.pec.2016.11.014.
.
.
Keywords: Children/Adolescents, Health Promotion, Vaccination, Infectious Diseases, Sexual Health, Prevention
de St Maurice A, Grijalva CG, Fonnesbeck C
Racial and regional differences in rates of invasive pneumococcal disease.
This study assessed the impact of introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) on pediatric IPD rates, as well as changes in racial and regional differences in invasive pneumococcal disease (IPD), in Tennessee. It found that PCV13 introduction led to substantial declines in childhood IPD rates and was associated with reduced regional and racial differences in IPD rates in Tennessee.
AHRQ-funded; HS022342.
Citation: de St Maurice A, Grijalva CG, Fonnesbeck C .
Racial and regional differences in rates of invasive pneumococcal disease.
Pediatrics 2015 Nov;136(5):e1186-94. doi: 10.1542/peds.2015-1773..
Keywords: Children/Adolescents, Vaccination, Prevention
Nace DA, Lin CJ, Ross TM
Randomized, controlled trial of high-dose influenza vaccine among frail residents of long-term care facilities.
The researchers compared high-dose to standard-dose inactivated influenza vaccine in residents of long-term-care facilities (LTCFs) during the 2011-2012 and 2012-2013 influenza seasons. They found that, among frail, elderly residents of LTCFs, high-dose influenza vaccine produced superior responses for all strains except influenza A(H1N1) in 2012-2013.
AHRQ-funded; HS023779.
Citation: Nace DA, Lin CJ, Ross TM .
Randomized, controlled trial of high-dose influenza vaccine among frail residents of long-term care facilities.
J Infect Dis 2015 Jun 15;211(12):1915-24. doi: 10.1093/infdis/jiu622.
.
.
Keywords: Elderly, Influenza, Long-Term Care, Prevention, Vaccination
Strohl AE, Mendoza G, Ghant MS
Barriers to prevention: knowledge of HPV, cervical cancer, and HPV vaccinations among African American women.
The overall goal of this study was to explore targetable barriers to HPV vaccination among African American women in an urban Chicago population. Most middle-aged African American women demonstrated low knowledge scores regarding HPV, cervical cancer, and the HPV vaccine. Education level, household income and having a child who had been offered the HPV vaccine were associated positively with adequate knowledge scores.
AHRQ-funded; HS021141.
Citation: Strohl AE, Mendoza G, Ghant MS .
Barriers to prevention: knowledge of HPV, cervical cancer, and HPV vaccinations among African American women.
Am J Obstet Gynecol 2015 Jan;212(1):65.e1-5. doi: 10.1016/j.ajog.2014.06.059..
Keywords: Prevention, Racial and Ethnic Minorities, Sexual Health, Urban Health, Vaccination, Women
Campbell LJ, Li Q, Li Y
Healthcare worker influenza vaccination in Oregon nursing homes: correlates of facility characteristics.
The authors identified nursing home (NH) characteristics that may be associated with employee influenza vaccination rates (EVRs). They concluded that, as NHs generally have low EVRs, it may be necessary to target low-performing facilities to achieve substantial improvements.
AHRQ-funded; HS000044.
Citation: Campbell LJ, Li Q, Li Y .
Healthcare worker influenza vaccination in Oregon nursing homes: correlates of facility characteristics.
J Am Med Dir Assoc 2014 Oct;15(10):768-72. doi: 10.1016/j.jamda.2014.06.005.
.
.
Keywords: Provider: Health Personnel, Influenza, Nursing Homes, Prevention, Vaccination
Perry LM, Winthrop KL, Curtis JR
Vaccinations for rheumatoid arthritis.
The goal of this paper is to highlight the most recent literature on the key vaccines and the specific considerations for the rheumatologist and their rheumatoid arthritis (RA) patients, with a particular focus on influenza, pneumococcal, and herpes zoster vaccines. It is important for rheumatologists to understand which vaccines are live and what potential contraindications exist for giving vaccines to RA patients.
AHRQ-funded; HS018517
Citation: Perry LM, Winthrop KL, Curtis JR .
Vaccinations for rheumatoid arthritis.
Curr Rheumatol Rep. 2014 Aug;16(8):431. doi: 10.1007/s11926-014-0431-x..
Keywords: Arthritis, Vaccination, Prevention